Urology Times staff

“Their opinions do need to be credible and be honest, but there is some component of being able to walk a line between providing a candid, unbiased opinion, and knowing that you are retained to represent a specific side in that case,” says Kenton H. Steele, Esq.

Susan F. Slovin, MD, PhD, highlights 177Lu-PSMA-617 and the radiopharmaceutical revolution in metastatic castration-resistant prostate cancer.

“[Patients] want to ensure that all of their episodes of UTIs are seen as a chronic condition that’s really debilitating in their life, and not just single episodes for which they need antibiotics,” says Victoria C. Scott, MD.

“Giving them options where they don’t need to necessarily jump to antibiotic therapy…are key aspects of management for a lot of these patients,” says Victoria C. Scott, MD.

"A lot of ancillary providers want more privileges that the physician has, and we have to be the guardians and the reason we're doing this is to protect our patients so that they get the best care available to them," says William C. Reha, MD, MBA.

“New and different drugs indicated at different points in the treatment cycle have been the biggest change," says 1 urologist.

“The frustration component that we found and heard amongst these women was with their providers really focusing their care around antibiotics…[and] not spending enough time on education with prevention strategies,” says Victoria C. Scott, MD.

In this interview, Marc A. Bjurlin, DO, MSc, FACOS, explains the advantages of prostate MRI, in which patients it is best used, and whether it can be considered the gold standard for prostate cancer detection

“Being able to have a follow-up visit that is convenient, that saves time, that saves money, but that can allow you to put everything together for the patient…is still a very valuable tool,” says Juan José Andino, MD.

“The feedback has been very positive from both physicians and patients,” author Madeline Zech Ruiz says of her book “I Married a Urologist.”

“With more people using [telehealth], with more people essentially forced by the pandemic to have to offer care at least at some point virtually, there is comfort and…more interest in ensuring that it remains an option,” says Juan José Andino, MD.

“Everybody in our department participates in some quantity of telehealth within their regular scheduled practice,” says Kara L. Watts, MD, in this video.

Daniel C. Danila, MD, discusses choosing among the androgen receptor inhibitors darolutamide, enzalutamide, and apalutamide when treating patients with castration-resistant prostate cancer.

“[Telemedicine is] not just a form of health care delivery for emergency pandemic situations, this is something that is here to stay,” says Kara L. Watts, MD, in this video.

"None of our patients had unexpected appointments that had to be made after their video encounters…supporting this idea that at least in urology, it seems that telehealth is a substitute for inpatient care when appropriately selected by the physician,” says Juan José Andino, MD.

Jingsong Zhang, MD, PhD, discusses how the site of metastases impacts his approach to treatment selection for patients with metastatic castration-resistant prostate cancer.

“It is always important to think about how the imaging and the way we read the imaging can improve, right and be used in a way that makes the most sense for the decision at hand,” says Stella K. Kang, MD, in this podcast.

Rohit Jain, MD, Moffitt Cancer Center, discusses risk status and other factors he considers in treatment selection for patients with advanced renal cell carcinoma.

Susan F. Slovin, MD, PhD, discusses the plethora of available treatment options and factors affecting treatment selection for patients with metastatic castration-sensitive prostate cancer.

Ninety-one percent of patients “felt very comfortable sharing sensitive information with the healthcare provider via the telehealth platform,” says Kara L. Watts, MD.

“It was quite a large subject to tackle,” Madeline Zech Ruiz says of her book, “I Married a Urologist.”

“Targeted ligand therapy is extremely exciting,” says Ketan K. Badani, MD.

Susan F. Slovin, MD, PhD, summarizes the key points urologists need to know about how PARP inhibitors are currently used in the prostate cancer paradigm.

Madeline Zech Ruiz discusses why she included chapters on premature ejaculation and genitourinary symptoms of menopause in her book “I Married a Urologist.”

The FDA has approved pembrolizumab plus lenvatinib for the first-line treatment of adult patients with advanced renal cell carcinoma.

“I would say, over the last several years, [MRI has] really become a popular thing to do prebiopsy,” says Ketan K. Badani, MD.

The SAP program cultivates a community of advocacy groups, medical associations, and medical institutions to foster collaboration and an open exchange of information among trusted peers for the ultimate benefit of patients and their families.

“One of the toughest parts about having a discussion with a patient about low-risk or early-stage prostate cancer…is actually deciding what might be best for that individual patient,” says Ketan K. Badani, MD.

The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting.

The targeted radioligand therapy achieved several other key end points beyond overall survival and radiographic progression-free survival.